Abstracts

NEW HEPATITIS B INFECTION AMONG HIV PATIENTS: WHO IS AT RISK?

New hepatitis B infection is infrequent but preventable. Vaccines and hepatitis B virus (HBV) specific antiretrovirals (ART) may offer protection for people living with HIV (PLWH). Hepatitis B in PLWH places them at increased risk for mortality compared to PLWH without HBV or those with HBV alone. We sought to examine the incidence of HBV…

TREATMENT WITH SOF/VEL/VOX IN HIV/HCV-COINFECTED PATIENTS PREVIOUSLY EXPOSED TO DAAs

Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is a pan-genotypic direct active antiviral (DAA) regimen approved for patients who have previously failed anti-HCV treatment with other DAAs. Little is known about the effectiveness of this regimen in HIV/HCV coinfected patients. We evaluated the effectiveness and safety of SOF/VEL/VOX in a prospective registry of coinfected patients treated with DAAs. For this…

CANNABIS USE AND HEPATIC STEATOSIS BY MRI-PDFF

There is conflicting evidence regarding the impact of cannabis use on liver steatosis in patients affected by HIV and HCV infections. We therefore assessed the relationship between the use of cannabis and hepatic steatosis in a cohort of people living with and without HIV and HCV. Cross-sectional analysis of the Miami Adult Studies on HIV…

METABOLIC-ASSOCIATED FATTY LIVER DISEASE AND ITS ASSOCIATION WITH EPICARDIAL FAT

Increasing evidence suggests fatty liver disease and metabolic conditions fall along a spectrum. An entity of metabolic associated fatty liver disease (MAFLD) has been recently proposed. We investigated the prevalence and factors associated with MAFLD, and associations with cardiovascular disease (CVD) in older people living with HIV(PWH). We conducted a cross-sectional assessment of CVD risk…